Lunai Bioworks Inc. (LNAI)
NASDAQ: LNAI · Real-Time Price · USD
1.240
-0.020 (-1.59%)
At close: Oct 8, 2025, 4:00 PM EDT
1.260
+0.020 (1.61%)
After-hours: Oct 8, 2025, 6:21 PM EDT

Company Description

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands.

It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.

It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.

The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025.

Lunai Bioworks Inc. is headquartered in Los Angeles, California.

Lunai Bioworks Inc.
Lunai Bioworks logo
CountryUnited States
IndustryBiotechnology
SectorHealthcare
Employees29
CEODavid Weinstein

Contact Details

Address:
2080 Century Park East, Suite 906
Los Angeles, California 90067
United States
Phone305 918 1980
Websitelunaibioworks.com

Stock Details

Ticker SymbolLNAI
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJuly - June
Reporting CurrencyUSD

Key Executives

NamePosition
David WeinsteinChief Executive Officer
Nathen FuentesChief Financial Officer